




# Motilal Oswal S&P BSE Healthcare ETF

(An open ended fund replicating/tracking the S&P BSE Healthcare  
Total Return Index)

Mar 24

# Veritable Ecosystem in Financial Services






**We have established experience in arguably most segments under financial services**

Source: MOAMC Internal, Data as on 31st December 2022.

# Motilal Oswal AMC Positioning

A lot of Fund Managers construct portfolios that are very close to the benchmark due to fear of significant underperformance

	Benchmark Agnostic	Benchmark Hugging	Benchmark Replicating
Style	Active	Active	Passive
Portfolio Holding	Focused	Closer to Benchmark	Same as benchmark
Alpha Generation Capacity	High	Low	NA
Motilal Oswal AMC			

Motilal Oswal AMC has benchmark agnostic products in the form of active mutual funds, PMS, AIF along with benchmark replicating index funds and ETFs

# Why Motilal Oswal AMC?

## Cornerstone of Investment Philosophy

### Focused Strategies

based on time tested investment framework

### Index-based Strategies

Index Funds and ETFs based on first principal of

**Q**

Quality of Business & Management

**G**

Growth in Earnings

**L**

Longevity of Quality and Growth

**P**

Price

**Easy**

To understand and track

**Economic**

Low cost

**Effective**

For wealth creation

# Motilal Oswal AMC in Numbers

## Investors

- More than **12 lac investors**
- More than **19 lac folios**

## Active Mutual Funds

- **10 active funds**
- Total AUM ~**30,000 crores**

## PMS and AIFs (Alternates)

- **20+ PMS and AIFs**
- Total AUM ~**20,000 crores**


## Index-Based Mutual Funds

- **30 Index Funds and ETFs**
- Total AUM ~**20,000 crores**

Source/Disclaimer: MOAMC Internal, Data as on 29-Feb-24

# The Covid-19 Catastrophe

# Pandemic made us realize importance of health system



*'There are decades where nothing happens, and there are weeks where decades happen'*

**–Vladmir Lenin  
(Former premier)**


Source/ Disclaimer: The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

# Healthcare Sector by the numbers



# Domestic healthcare sector on a strong footing


Rising income, increasing awareness, lifestyle diseases and increased access to insurance, suggests that healthcare sector will note robust growth



Source: NITI Ayog, Frost & Sullivan, LSI Financial Services, Deloitte. Bookmyforex for historical USD/INR values & 28/03/2022 value of USD/INR for 2022 F data. Data as per latest available report as of 30 March 2021. The above graph is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

# Sector will be aided by increased government spending

The domestic healthcare sector will get shot in the arm as the Government plans to amp up spending and provide healthcare facilities to the economically weaker section



Source/ Disclaimer: indiabudget.gov.in. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

# India- The pharmacy of the world

Domestic pharma market is pegged at **\$42 Billion** in 2021 and is expected to reach **\$130 Billion** by 2030



Accounts for  
**50%**  
of global vaccine  
supplies

**3<sup>rd</sup>** Largest  
market by volume



**14<sup>th</sup>** Largest  
market by value

**Largest**  
provider of generic  
drugs globally



Source/ Disclaimer: IBEF. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

# Inadequate healthcare infrastructure indicates tremendous growth opportunity

India's doctor-population ratio and bed density ratio vis-à-vis other economies is relatively lower indicating strong growth potential

**Doctors**  
(per 10,000 population) <sup>[1]</sup>




**16**



**09**

**Hospital Bed density (per 10,000 population) <sup>[2]</sup>**




Source: [1] WHO World Health Statistics 2020, [2] India bed density is estimated by CRISIL Research, tracking Universal health Coverage- 2017 Global Monitoring Report, World Bank Data base, CRISIL Research. The above graph is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

# Tailwinds for Diagnostics

- Domestic diagnostic industry estimated at ~\$9 **Billion** (2020) and is expected to grow at over 10% over next 5 years
- The diagnostics business is **asset light** model as it operates on hub and spoke model
- Only 20% of total diagnostic services are reimbursed via insurance claims, rest is out of pocket expense
- Inclusion of diagnostic tests under insurance coverage may lead to inflection in growth rate of the industry

India's out of pocket spending is at elevated levels (%)



Source: WHO, Kotak Institutional Equities


Source: Edelweiss Professional Investor Research 2020, Kotak Institutional Equity. The above graph is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

# India poised to be an attractive destination for Medical Tourism

- Medical tourism business pegged at \$5 billion in 2020
- Expected to become a \$14 billion business by 2023
- Medical tourism expected to grow at ~21% CAGR between 2020-27

Treatment costs in India well below global costs  
Medical tourism Treatment cost (US\$)


Treatment	US	UK	Thailand	Singapore	India
Heart Surgery	100,000	40,000	14,000	15,000	5,000
Bone Marrow Transplant	250,000	290,000	62,000	150,000	30,000
Liver Transplant	300,000	200,000	75,000	140,000	45,000
Knee Replacement	48,000	50,000	8,000	25,000	6,000



**India ranked #10<sup>th</sup> out of the top 46 countries for medical tourism**

Source/Disclaimer: Average cost of treatment;- Kotak Institutional Equities, Market size- Trade promotion council of India & Kotak Institutional Equities. #medical tourism Index 2020-2021. The graphic is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

# Key Growth Drivers



Source/Disclaimer: \*100% FDI permitted under automatic route in the hospital sector. In the pharmaceutical sector, 100% FDI in green field projects and 74% in brownfield projects. The graphic is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

# About Motilal Oswal S&P BSE Healthcare ETF



# Motilal Oswal S&P BSE Healthcare ETF



## Type of Scheme

An open ended fund replicating/tracking S&P BSE Healthcare Total Return Index



## Minimum Application Lot Size

**On Exchange** – Investors can buy/sell units of the Scheme in round lot of 1 unit and in multiples thereafter

(BSE: 543563 , NSE: MOHEALTH)

**Directly with Mutual Fund** – Buy/sell units of the Scheme where the subscription/redemption amount is in excess of INR 25 crs.



## Inception Date

29-Jul-2022



## Benchmark

S&P BSE Healthcare TRI



## Investment Objective

The investment objective of the scheme is to provide returns that, before expenses, correspond to the total returns of the securities as represented by S&P BSE Healthcare TRI, subject to tracking error. However, there is no guarantee or assurance that the investment objective of the scheme will be achieved



## Exit Load

Nil



## Fund Manager

Mr. Swapnil Mayekar &  
Mr. Rakesh Shetty (Debt component)





## Total Expense Ratio

Regular – 0.22%

Source/Disclaimer: MOAMC. Data as on 31-Mar-24 Mutual funds are subject to market risk, read all scheme documents carefully

# Product suitability


Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p><b>Motilal Oswal S&amp;P BSE Healthcare ETF</b> (An open ended fund replicating / tracking the S&amp;P BSE Healthcare Total Return Index)</p>	<ul style="list-style-type: none"> <li>• Return that corresponds to the total returns of the S&amp;P BSE Healthcare Total Return Index subject to tracking error</li> <li>• Long term capital growth</li> </ul>	<p>Fund</p> 	<p>S&amp;P BSE Healthcare Total Return Index</p> 

# S&P BSE Healthcare Index

# About: S&P BSE Healthcare Total Return Index

**Index Objective:** The S&P BSE Healthcare Total Return Index is designed to provide investors exposure to companies included in the S&P BSE AllCap that are classified as members of the healthcare sector.

## Index Methodology Snapshot:




Source/Disclaimer: S&P BSE. Data as on 31-Mar-24 \*for detailed index methodology kindly visit <https://www.spglobal.com/spdji/en/>

# S&P BSE Healthcare Index snapshot


## Top 10 Constituents

S. No.	Constituent Name	Weight
1	Sun Pharmaceutical Industries Ltd	17.7%
2	Cipla Ltd/India	8.2%
3	Dr Reddy'S Laboratories Ltd	7.6%
4	Apollo Hospitals Enterprise Ltd	6.5%
5	Max Healthcare Institute Ltd	6.1%
6	Divi'S Laboratories Ltd	4.4%
7	Lupin Ltd	3.9%
8	Aurobindo Pharma Ltd	3.1%
9	Zydus Lifesciences Ltd	2.6%
10	Torrent Pharmaceuticals Ltd	2.4%
--	<b>Total</b>	<b>62.4%</b>

## Basic Industry (AMFI): S&P BSE Healthcare Index




## S&P BSE Healthcare TR



Source/Disclaimer: S&P BSE. Data as on 31-Mar-24 Basic Industry Sectors as per AMFI Industry Classification. The stocks/sectors mentioned above are used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy. The stock may or may not be part of our portfolio/strategy/ schemes. It should not be construed as investment advice to any party. Past performance may or may not be sustained in future.


# Sneak peek into industries forming part of the index



Source/ Disclaimer: The stocks/sectors mentioned above are used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy. The stock may or may not be part of our portfolio/strategy/ schemes. It should not be construed as investment advice to any party

# Long term historical outperformance


S&P BSE Healthcare Total Return Index has significantly outperformed the broad market over the last 15 years



Source/Disclaimer: S&P BSE. Performance as of close of 30-Jun-07 to 31-Mar-24 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

# Calendar Year Performance

S&P BSE Healthcare Index has outperformed against S&P BSE All Cap Index in **8** out of last **15** calendar years



Source/Disclaimer: S&P BSE. Performance as of close of 31-Dec-07 to 31-Mar-24 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.



# Risk-Return Profile

Data Label		1 year	3 year	5 year	10 year	15 year
<b>S&amp;P BSE Healthcare TRI</b>	<b>CAGR</b>	61.3%	18.8%	20.3%	14.0%	19.1%
S&P BSE AllCap TRI		41.8%	20.0%	17.8%	16.1%	17.5%
<b>S&amp;P BSE Healthcare TRI</b>	<b>Annualised Volatility</b>	11.8%	13.8%	17.5%	17.6%	16.9%
S&P BSE AllCap TRI		10.3%	13.9%	18.5%	16.3%	17.4%
<b>S&amp;P BSE Healthcare TRI</b>	<b>Risk Adjusted Returns</b>	5.188	1.364	1.162	0.796	1.133
S&P BSE AllCap TRI		4.059	1.439	0.962	0.989	1.005

Source/Disclaimer: S&P BSE: Performance as of close of 31-Mar-09 to 31-Mar-24. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

# Index SIP Returns

S&P BSE Healthcare TRI	1 Year	3 Year	5 Year	10 Year
<b>Returns</b>	56.9%	24.2%	23.7%	14.7%
<b>Amount Invested</b>	1,20,000	3,60,000	6,00,000	12,00,000
<b>Market Value</b>	1,53,644	5,10,538	10,77,816	25,89,013

Data as of close of Mar 31, 2024 For SIP returns, monthly investment of INR 10,000/- invested on the first business day of every month has been considered. Performance is calculated using Total Return Index, with zero cost/expenses. Past performance may or may not be sustained in the future


Source/Disclaimer: S&P BSE: Performance as of close of 01-Apr-14 to 31-Mar-24. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy. The SIP amount, tenure of SIP, expected rate of return are assumed figures for the purpose of explaining the concept of advantages of SIP investments. The actual result may vary from depicted results depending on scheme selected. It should not be construed to be indicative of scheme performance in any manner. The above are not scheme SIP returns, but simulation of index SIP returns. Past performance may or may not be sustained in future.

# Better odds of double-digit returns!

	3 Year Rolling Returns		5 Year Rolling Returns	
	S&P BSE Healthcare TRI	S&P BSE Allcap TRI	S&P BSE Healthcare TRI	S&P BSE Allcap TRI
Average	16.2%	13.1%	14.9%	12.4%
Median	18.0%	13.3%	14.0%	13.2%
Min	-9.8%	-5.9%	-6.4%	-1.8%
Max	43.2%	35.1%	33.8%	24.3%
Returns Range	% of observations			
Negative	16.9%	4.5%	5.0%	1.0%
0% to 10%	5.4%	28.3%	21.5%	28.0%
10% to 15%	11.3%	26.2%	27.2%	35.3%
15% to 20%	77.7% { 26.5%	67.2% { 22.0%	73.6% { 16.7%	71.0% { 34.3%
Above 20%	39.9%	19.0%	29.7%	1.5%

Source/Disclaimer: S&P BSE. 250 trading days assumed in one year. S&P BSE. Performance as of close of 31-May-07 to 31-Mar-24 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

# Drawdowns over 15 years



Source/Disclaimer: S&P BSE. Performance as of close of 31-May-07 to 31-Mar-24 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

# Performance across market cycles


Market Cycle	Nifty 50 TRI	S&P BSE Healthcare TRI	S&P BSE AllCap TRI
<b>Bull</b>	27.3%	10.3%	17.7%
<b>Bear</b>	-38.8%	-18.1%	-42.4%
<b>Recovery</b>	34.2%	41.0%	37.9%

- Healthcare sector tends to be a defensive play
- The S&P BSE healthcare Index has historically outperformed the broader benchmarks during Bear and recovery market cycles

Source/Disclaimer: niftyindices, S&P BSE, MOAMC Research. Performance as of close of 31-May-07 to 31-Mar-24. All Performance numbers in CAGR. Bear market defined as >20% fall from peak to trough. Recovery defined as the recovery from trough to previous peak. Bull market defined as rising market after recovery. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

# Annexure


# Healthcare Industry Breakup



Source/Disclaimer: S&P BSE, Nifty Indices. Performance as of close of 30-Sep-2018 to 31-Mar-24 . Size classification as per AMFI; . The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

# Exposure to All Caps

S&P BSE Healthcare Index has healthy mix of Large Mid and Small Cap Stocks



Source/Disclaimer: S&P BSE, Nifty Indices. Performance as of close of 30-Sep-2018 to 31-Mar-24. Basic Industry as per AMFI Industry Classification. The industries mentioned above are used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy. The sectors may or may not be part of our portfolio/strategy/schemes. It should not be construed as investment advice to any party.




# Performance vs Nifty 50

Data Label		1 year	3 year	5 year	10 year	15 year
<b>S&amp;P BSE Healthcare TRI</b>	<b>CAGR</b>	<b>61.3%</b>	<b>18.8%</b>	<b>20.3%</b>	<b>14.0%</b>	<b>19.1%</b>
Nifty 50 TRI		30.1%	16.3%	15.3%	14.2%	15.6%
<b>S&amp;P BSE Healthcare TRI</b>	<b>Annualised Volatility</b>	<b>11.8%</b>	<b>13.8%</b>	<b>17.5%</b>	<b>17.6%</b>	<b>16.9%</b>
Nifty 50 TRI		9.7%	13.7%	19.0%	16.5%	18.0%
<b>S&amp;P BSE Healthcare TRI</b>	<b>Risk Adjusted Returns</b>	<b>5.188</b>	<b>1.364</b>	<b>1.162</b>	<b>0.796</b>	<b>1.133</b>
Nifty 50 TRI		3.087	1.192	0.802	0.861	0.867

Source/Disclaimer: S&P BSE, Nifty Indices. Performance as of close of 31-Mar-09 to 31-Mar-24 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.


# Indian healthcare still at a nascent stage

Per capita healthcare spending remains one of the lowest globally  
March fiscal year-end, 2021 (USD)




Source: WHO, Kotak Institutional Equities

Spend on healthcare in the consumption mix set to increase (%)




Source: McKinsey, Kotak Institutional Equities

India healthcare market break-up by revenue  
March fiscal year-end, 2021 (%)




India needs to add 1.5 mn additional beds over the next decade



Source/Disclaimer: Kotak Institutional Equities; Data as per latest available report as of June 2022. The above graph is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

# eHealth- a new norm in post Covid era

On the back of rapid digitization and increased government support **India's eHealth market is estimated to touch \$10.6bn by 2025**



- eHealth includes teleconsulting, e-pharmacies, e-diagnostics and online fitness and wellness.
- With dual benefit of lower price and more convenience we may see increased adoption of the services.

Source/ Disclaimer: INC42- Decoding ehealth opportunity. Article published on Jan 2021. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

# Motilal Oswal S&P BSE Healthcare Performance

# Motilal Oswal Enhanced Value ETF Performance

## Lumpsum Performance

	1 Year		3 Year		5 Year		7 Year		Since Inception	
	Simple annualized (%)	Current Value of Investment of Rs. 10,000	CAGR (%)	Current Value of Investment of Rs. 10,000	CAGR (%)	Current Value of Investment of Rs. 10,000	CAGR (%)	Current Value of Investment of Rs. 10,000	CAGR (%)	Current Value of Investment of Rs. 10,000
Motilal Oswal S&P BSE Healthcare ETF	61.2	16,077	-	-	-	-	-	-	29.7	15,415
S&P BSE Healthcare TRI	61.7	16,127	-	-	-	-	-	-	30.1	15,491
Nifty 50 TRI	30.3	13,008	-	-	-	-	-	-	18.2	13,219
NAV (Rs.) Per Unit as on: (28-Mar-2024) 35.3017	21.9582		-		-		-		22.9016	

Date of Inception: 29-Jul-2022

## SIP Performance

	1 Year			3 Year			5 Year			Since Inception		
	Scheme	S&P BSE Low Volatility TRI	Nifty 50 TRI	Scheme	S&P BSE Low Volatility TRI	Nifty 50 TRI	Scheme	S&P BSE Low Volatility TRI	Nifty 50 TRI	Scheme	S&P BSE Low Volatility TRI	Nifty 50 TRI
Invested amount (₹)	1,20,000	1,20,000	1,20,000	-	-	-	-	-	-	1,70,000	1,70,000	1,70,000
Market value (₹)	1,53,374	1,53,644	1,37,018	-	-	-	-	-	-	2,44,115	2,44,818	2,08,484
Returns (CAGR %)	56.4%	56.9%	27.8%	-	-	-	-	-	-	42.7%	43.1%	22.5%

Source/Disclaimer: MOAMC. Data as on 31-Mar-24 The NAV per unit shown in the table is as on the start date of the said period. Past performance may or may not be sustained in the future. Performance is for Regular Plan Growth Option. Different plans have different expense structure. For SIP returns, monthly investment of INR 10,000/- invested on the first business day of every month has been considered. Mr. Swapnil Mayekar is the Fund Manager since Inception and he manages 30 schemes of Motilal Oswal Mutual Fund.

# Performance of other schemes managed by Swapnil Mayekar

Name of Fund Manager: Swapnil Mayekar						
Period	1 year		3 year		5 year	
	Scheme Return (%)	Benchmark Return (%)	Scheme Return (%)	Benchmark Return (%)	Scheme Return (%)	Benchmark Return (%)
Motilal Oswal S&P BSE Enhanced Value ETF	91.7	92.9	-	-	-	-
Motilal Oswal S&P BSE Enhanced Value Index Fund	88.9	92.9	-	-	-	-
Motilal Oswal Nifty 200 Momentum 30 ETF	69.8	70.5	-	-	-	-
Motilal Oswal Nifty Bank Index Fund	15.9	17.1	11.8	13.0	-	-
Motilal Oswal Nifty 50 Index Fund	29.5	30.3	15.6	16.3	-	-
Motilal Oswal Nifty 50 ETF (Formerly known as Motilal Oswal M50 ETF)	30.2	30.3	16.3	16.3	15.0	15.3

**Note:**

- Swapnil Mayekar manages 21 schemes of Motilal Oswal Mutual Fund.
- In case the number of schemes managed by a fund manager is more than six, performance data of top 3 and bottom 3 schemes managed by fund manager has been provided herein.
- Period for which scheme's performance has been provided is computed basis last day of the month-end preceding the date of advertisement.
- Different plans shall have a different expense structure. The performance details provided herein are of Regular plan.

Source/Disclaimer: MOAMC. Data as on 31-Mar-24 . Past performance may or may not be sustained in the future. Performance is for Regular Plan Growth Option. Different plans have different expense structure.

# Performance of other schemes managed by Rakesh Shetty

Name of Fund Manager: Rakesh Shetty						
Period	1 year		3 year		5 year	
	Scheme Return (%)	Benchmark Return (%)	Scheme Return (%)	Benchmark Return (%)	Scheme Return (%)	Benchmark Return (%)
Motilal Oswal S&P BSE Enhanced Value ETF#	91.7	92.9	-	-	-	-
Motilal Oswal S&P BSE Enhanced Value Index Fund#	88.9	92.9	-	-	-	-
Motilal Oswal Nifty 200 Momentum 30 ETF#	69.8	70.5	-	-	-	-
Motilal Oswal Ultra Short Term Fund	6.0	7.8	4.2	6.0	4.4	6.2
Motilal Oswal Liquid Fund	6.7	7.3	5.0	5.5	4.6	5.3
Motilal Oswal Nifty 5 Year G-Sec Fund of Fund	7.1	7.7	-	-	-	-

Note:


- Rakesh Shetty manages 29 schemes of Motilal Oswal Mutual Fund.
- In case the number of schemes managed by a fund manager is more than six, performance data of top 3 and bottom 3 schemes managed by fund manager has been provided herein.
- Period for which scheme's performance has been provided is computed basis last day of the month-end preceding the date of advertisement.
- Different plans shall have a different expense structure. The performance details provided herein are of Regular plan.

Source/Disclaimer: MOAMC. Data as on 31-Mar-24 . #Only debt component is managed by Rakesh Shetty. Past performance may or may not be sustained in the future. Performance is for Regular Plan Growth Option. Different plans have different expense structure.


# Motilal Oswal Passive Fund Offerings



# Motilal Oswal Passive Fund Offerings



# Motilal Oswal Passive Fund Offerings



# Motilal Oswal Passive Fund Offerings



# Motilal Oswal Passive Fund Offerings

Motilal Oswal 5 Year  
G-Sec Fund of Fund

Motilal Oswal Nifty 5 year  
Benchmark G-Sec ETF



Motilal Oswal Asset Allocation  
Passive Fund of Fund - Aggressive









Motilal Oswal Asset Allocation  
Passive Fund of Fund - Conservative



Motilal Oswal Gold and Silver  
ETFs Fund of Funds











# Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p><b>Motilal Oswal Nifty 50 Index Fund</b> (An open ended scheme replicating / tracking Nifty 50 Total Return Index)</p>	<ul style="list-style-type: none"> <li>• Long term capital growth</li> <li>• Return that corresponds to the performance of the Nifty 50 Total Return Index, subject to tracking error</li> <li>• Investment in securities constituting Nifty 50 Total Return Index</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>Nifty 50 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Nifty Next 50 Index Fund</b> (An open ended scheme replicating / tracking Nifty Next 50 Total Return Index)</p>	<ul style="list-style-type: none"> <li>• Return that corresponds to the performance of Nifty Next 50 Total Return Index subject to tracking error</li> <li>• Investment in securities constituting of Nifty Next 50 Index</li> <li>• Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>Nifty Next 50 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Nifty Midcap 150 Index Fund</b> (An open ended scheme replicating / tracking Nifty Midcap 150 Total Return Index)</p>	<ul style="list-style-type: none"> <li>• Return that corresponds to the performance of Nifty Midcap 150 Total Return Index, subject to tracking error</li> <li>• Investment in securities constituting Nifty Next 50 Index</li> <li>• Long-term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>Nifty Midcap 150 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Nifty Smallcap 250 Index Fund</b> (An open ended scheme replicating / tracking Nifty Smallcap 250 Total Return Index)</p>	<ul style="list-style-type: none"> <li>• Return that corresponds to the performance of Nifty Smallcap 250 Total Return Index, subject to tracking error</li> <li>• Investment in securities constituting Nifty Small cap 250 Index</li> <li>• Long-term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>Nifty Smallcap 250 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>

\*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.











# Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p><b>Motilal Oswal Nifty 500 Index Fund</b> (formerly known as Motilal Oswal Nifty 500 Fund) (An open ended scheme replicating / tracking Nifty 500 Total Return Index)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the performance of Nifty 500 Total Return Index, subject to tracking error</li> <li>Investment in securities constituting Nifty 500 Index</li> <li>Long-term capital growth</li> </ul>	<p>Fund</p>  <p>Riskometer Investors understand that their principal will be at Very High risk</p>	<p>Nifty 500 Total Return Index</p>  <p>Riskometer Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Nifty 50 ETF</b> (Formerly known as Motilal Oswal M50 ETF) (An open ended scheme replicating/tracking Nifty 50 Total Return Index) BSE: 590115, NSE: MOM50</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the performance of the Nifty 50 Total Return Index, subject to tracking error</li> <li>Investment in securities constituting Nifty 50 Total Return Index</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p>Riskometer Investors understand that their principal will be at Very High risk</p>	<p>Nifty 50 Total Return Index</p>  <p>Riskometer Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Nifty Midcap 100 ETF</b> (Formerly known as Motilal Oswal Nifty Midcap 100 ETF) (An open ended scheme replicating/tracking Nifty Midcap 100 Total Return Index) BSE: 536960, NSE: MOM100</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the performance of Nifty Midcap 100 Total Return Index, subject to tracking error</li> <li>Investment in securities constituting Nifty Midcap 100 Index</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p>Riskometer Investors understand that their principal will be at Very High risk</p>	<p>Nifty Midcap 100 Total Return Index</p>  <p>Riskometer Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Nifty Bank Index Fund</b> (An open ended scheme replicating / tracking Nifty Bank Total Return Index)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the performance of Nifty Bank Total Return Index, subject to tracking error</li> <li>Investment in securities constituting Nifty Bank Index</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p>Riskometer Investors understand that their principal will be at Very High risk</p>	<p>Nifty Bank Total Return Index</p>  <p>Riskometer Benchmark riskometer is at Very High risk</p>







\*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

# Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p><b>Motilal Oswal S&amp;P 500 Index Fund</b> (An open ended scheme replicating / tracking S&amp;P 500 Total Return Index)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the performance of S&amp;P 500 Total Return Index subject to tracking error</li> <li>Investment in securities constituting S&amp;P 500 Index</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>S&amp;P 500 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal NASDAQ 100 ETF</b> (An open ended scheme replicating/tracking NASDAQ-100 Total Return Index) BSE: 533385, NSE: MOFN100)</p>	<ul style="list-style-type: none"> <li>Return that corresponds generally to the performance of NASDAQ 100 Total Returns Index, subject to tracking error</li> <li>Investment in securities constituting of NASDAQ 100 Index</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>NASDAQ 100 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal NASDAQ 100 Fund of Fund</b> (An open ended fund of fund scheme investing in Motilal Oswal Nasdaq 100 ETF)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the performance of the NASDAQ-100 Total Returns Index, subject to tracking error</li> <li>Investment in securities constituting of NASDAQ-100 ETF</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>NASDAQ 100 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Asset Allocation Passive Fund of Fund – Aggressive</b> (An open ended fund of funds scheme investing in passive funds)</p>	<ul style="list-style-type: none"> <li>To generate long term growth/capital appreciation by offering asset allocation.</li> <li>Investment solution that predominantly invests in passive funds such as ETF/Index Funds of equity and equity related instruments (domestic as well as international), fixed income and Gold</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>50% Nifty 500 TRI + 20% S&amp;P 500 TRI (INR) + 10% Domestic Price of Gold + 20% Nifty 5 Yr Benchmark G-Sec Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>

\*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.







# Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p><b>Motilal Oswal Asset Allocation Passive Fund of Fund – Conservative</b> (An open ended fund of funds scheme investing in passive funds)</p>	<ul style="list-style-type: none"> <li>To generate long term growth/capital appreciation by offering asset allocation.</li> <li>Investment solution that predominantly invests in passive funds such as ETF/Index Funds of equity and equity related instruments (domestic as well as international), fixed income and Gold</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at High risk</p>	<p>30% Nifty 500 TRI + 10% S&amp;P 500 TRI (INR) + 10% Domestic Price of Gold + 50% Nifty 5 Yr Benchmark G-Sec Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at High risk</p>
<p><b>Motilal Oswal Nifty 5 YR Benchmark G Sec ETF</b> (formerly known as Motilal Oswal 5 Year G – Sec ETF) (An open ended scheme replicating/tracking Nifty 5 yr. Benchmark G-Sec Total Return Index) (A-III A relatively low interest rate risk and relatively low credit risk) BSE: 543250, NSE: MOGSEC</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the performance of the Nifty 5 yr Benchmark G-Sec Total Return Index, subject to tracking error</li> <li>Investment in securities constituting of Nifty 5 yr Benchmark G-Sec Index</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Moderate risk</p>	<p>Nifty 5 yr Benchmark G-Sec Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Moderate risk</p>
<p><b>Motilal Oswal 5 Year G-Sec Fund of Fund</b> (An open ended fund of funds scheme investing in units of Motilal Oswal Nifty 5 YR Benchmark G-Sec ETF) (A-III A relatively low interest rate risk and relatively low credit risk)</p>	<ul style="list-style-type: none"> <li>Long term capital appreciation</li> <li>Return that corresponds to the performance of Motilal Oswal 5 Year G-Sec ETF through investment in its units.</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Moderate risk</p>	<p>Nifty 5 yr Benchmark G-Sec Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Moderate risk</p>

\*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.











# Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p><b>Motilal Oswal NASDAQ Q 50 ETF</b> (An open ended scheme replicating/ tracking Nasdaq Q-50 TR Index) BSE: 543437, NSE: MONQ50</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the performance of the NASDAQ Q-50 Total Return Index subject to tracking error and forex movement.</li> <li>Long term capital growth.</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>NASDAQ Q-50 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Nifty 200 Momentum 30 ETF</b> (An open ended fund replicating / tracking the Nifty 200 Momentum 30 Total Return Index (BSE: 543465, NSE: MOMOMENTUM))</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the total returns of the Nifty 200 Momentum 30 Total Return Index subject to tracking error</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>Nifty 200 Momentum 30 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Nifty 200 Momentum 30 Index Fund</b> (An open ended fund replicating / tracking the Nifty 200 Momentum 30 Total Return Index)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the total returns of the Nifty 200 Momentum 30 Total Return Index subject to tracking error</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>Nifty 200 Momentum 30 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>




\*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

# Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p><b>Motilal Oswal S&amp;P BSE Low Volatility ETF</b> (An open ended fund replicating / tracking the S&amp;P BSE Low Volatility Total Return Index BSE: 543501, NSE: MOLOWVOL)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the total returns of the S&amp;P BSE Low Volatility Total Return Index subject to tracking error</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>S&amp;P BSE Low Volatility Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal S&amp;P BSE Low Volatility Index Fund</b> (An open ended fund replicating / tracking the S&amp;P BSE Low Volatility Total Return Index)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the total returns of the S&amp;P BSE Low Volatility Total Return Index subject to tracking error</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>S&amp;P BSE Low Volatility Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal S&amp;P BSE Financials ex Bank 30 Index Fund</b> (An open ended fund replicating / tracking the S&amp;P BSE Financials ex Bank 30 Total Return Index)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the total returns of the S&amp;P BSE Financials ex Bank 30 Total Return Index subject to tracking error</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>S&amp;P BSE Financials ex Bank 30 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal S&amp;P BSE Healthcare ETF</b> (An open ended fund replicating / tracking the S&amp;P BSE Healthcare Total Return Index) BSE: 543563, NSE: MOHEALTH</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the total returns of the S&amp;P BSE Healthcare Total Return Index subject to tracking error</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>S&amp;P BSE Healthcare Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>









\*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

# Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p><b>Motilal Oswal S&amp;P BSE Quality ETF</b> (An open ended fund replicating / tracking the S&amp;P BSE Quality Total Return Index) BSE: 543577, NSE: MOQUALITY</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the total returns of the S&amp;P BSE Quality Total Return Index subject to tracking error</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>S&amp;P BSE Quality Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal S&amp;P BSE Quality Index Fund</b> (An open ended fund replicating / tracking the S&amp;P BSE Quality Total Return Index)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the total returns of the S&amp;P BSE Quality Total Return Index subject to tracking error</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>S&amp;P BSE Quality Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal S&amp;P BSE Enhanced Value ETF</b> (An open ended fund replicating / tracking the S&amp;P BSE Enhanced Value Total Return Index) BSE:543576, NSE: MOVALUE</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the total returns of the S&amp;P BSE Enhanced Value Total Return Index subject to tracking error</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>S&amp;P BSE Enhanced Value Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal S&amp;P BSE Enhanced Value Index Fund</b> (An open ended fund replicating / tracking the S&amp;P BSE Enhanced Value Total Return Index)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the total returns of the S&amp;P BSE Enhanced Value Total Return Index subject to tracking error</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>S&amp;P BSE Enhanced Value Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>





\*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

# Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p><b>Motilal Oswal Gold and Silver ETFs Fund of Funds</b> (An open ended fund of funds scheme investing in units of gold and silver exchange traded funds)</p>	<ul style="list-style-type: none"> <li>• Long term capital appreciation</li> <li>• Return that corresponds to the performance of the underlying Schemes of Gold ETF and Silver ETF</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>LBMA Price of Gold and Silver</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Nifty Microcap 250 Index Fund</b> (An open ended scheme replicating / tracking Nifty Microcap 250 Total Return Index)</p>	<ul style="list-style-type: none"> <li>• Return that corresponds to the total returns of Nifty Microcap 250 Total Return Index, subject to tracking error</li> <li>• Long-term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>Nifty Microcap 250 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal S&amp;P Developed markets Ex-US FoF</b> (An open-ended fund of funds scheme investing in units of Global ETFs which track the performance of Developed Markets excluding US)</p>	<ul style="list-style-type: none"> <li>• Long term capital appreciation.</li> <li>• To invest in global ETFs which track the performance of Developed Markets exUS</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>S&amp;P Developed Ex-U.S. BMI Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Nifty 500 ETF</b> (An open ended scheme replicating / tracking Nifty 500 Total Return Index)</p>	<ul style="list-style-type: none"> <li>• Return that corresponds to the total returns of Nifty 500 Total Return Index, subject to tracking error</li> <li>• Long-term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>Nifty 500 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>

\*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

# Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p><b>Motilal Oswal Nifty Smallcap 250 ETF</b> (An open-ended fund replicating / tracking the Nifty Smallcap 250 Total Return Index)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the total returns of the Nifty Smallcap 250 Total Return Index, subject to tracking error.</li> <li>Long term capital growth</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>Nifty Smallcap 250 Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>
<p><b>Motilal Oswal Nifty Realty ETF</b> (An open ended scheme replicating / tracking Nifty Realty Total Return Index)</p>	<ul style="list-style-type: none"> <li>Return that corresponds to the performance of Nifty Realty Total Return Index subject to tracking error.</li> <li>Long term capital growth.</li> </ul>	<p>Fund</p>  <p><b>Riskometer</b> Investors understand that their principal will be at Very High risk</p>	<p>Nifty Realty Total Return Index</p>  <p><b>Riskometer</b> Benchmark riskometer is at Very High risk</p>

\*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

# Thank you

---

“An investor might be Better off buying the market”

- **By Warren Buffett**

## **Contact Us -**

Speak: +91-22 40548002 | 8108622222

Write: [mfservice@motilaloswal.com](mailto:mfservice@motilaloswal.com)

Visit: [www.motilaloswalmf.com](http://www.motilaloswalmf.com)